Taiji Group (600129.SH) subsidiary Buprenorphine Tartrate Injection has obtained a drug registration certificate.

Zhitong Finance APP news, Taiji Group (600129.SH) announced that recently, its holding subsidiary Southwest Pharmaceutical Co., Ltd. received the "Drug Registration Certificate" for Butorphanol Tartrate Injection issued by the National Medical Products Administration. This drug is suitable for the treatment of various cancer pain and postoperative pain. The approval of the "Drug Registration Certificate" signifies that it has passed the consistency evaluation of quality and efficacy for generic drugs and will further enrich the company's product line.